doi: 10.3389/adar.2023.10901 Received 13 September 2022 Accepted 09 January 2023 Published 18 January 2023 Volume 3 - 2023 Edited by Emmanuel Onaivi, William Paterson University, United States Reviewed by Qing-Rong Liu, National Institute on Aging (NIH), United States Syed Ali, National Center for Toxicological Research (FDA), United States Updates Copyright 2023 Virmani
Side effects are generally mild when treatment is administered by a qualified practitioner using approved, clinical-grade formulations
Some individuals may experience mild discomfort, irritation, or an urge to defecate after inserting a suppository
This includes exploring peptides Read Articles Exploring Retatrutide: A Promising Triple Agonist in Human Trails for Obesity and Type 2 Diabetest Enter retatrutide (LY3437943), a novel triple hormone receptor agonist developed by Eli Lilly, targeting glucose-dependent insulinotropic Read Articles What is NAD+